5α-reductase type 3 enzyme in benign and malignant prostate
| Autor: | Alejandro Godoy, James L. Mohler, Yun Li, Gary J. Smith, Mark Titus, Varun Maher, Olga G. Kozyreva |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
chemistry.chemical_classification
medicine.medical_specialty Urology Biology medicine.disease Dutasteride Isozyme 5α reductase Prostate cancer chemistry.chemical_compound Endocrinology Enzyme medicine.anatomical_structure Oncology chemistry Prostate Internal medicine Dihydrotestosterone Gene expression medicine Cancer research medicine.drug |
| Zdroj: | The Prostate. 74:235-249 |
| ISSN: | 0270-4137 |
| DOI: | 10.1002/pros.22745 |
| Popis: | BACKGROUND Currently available 5α-reductase inhibitors are not completely effective for treatment of benign prostate enlargement, prevention of prostate cancer (CaP), or treatment of advanced castration-recurrent (CR) CaP. We tested the hypothesis that a novel 5α-reductase, 5α-reductase-3, contributes to residual androgen metabolism, especially in CR-CaP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text